

LISTING OF THE CLAIMS:

1 – 49. (canceled).

50. (new) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of

- (a) a mature form of amino acid sequence SEQ ID No. 2;
- (b) an amino acid sequence of SEQ ID NO: 2; and
- (c) a nucleic acid molecule comprising the complement thereof.

51. (new) The nucleic acid molecule according to Claims 50 wherein the nucleic acid molecule differs by a single nucleotide from a nucleic acid sequence of SEQ ID NO: 1.

52. (new) The nucleic acid molecule according to Claim 50 wherein said nucleic acid molecule comprises a nucleotide sequence consisting of SEQ ID NO:1.

53. (new) The nucleic acid molecule according to Claim 50 wherein said nucleic acid molecule hybridizes under stringent conditions to a nucleotide sequence of SEQ ID NO:1 or a complement of said nucleotide sequence.

54. (new) A vector comprising the nucleic acid molecule according to Claim 50.

55. (new) The vector according to Claim 54 further comprising a promoter operably-linked to said nucleic acid molecule.

56. (new) A cell comprising a vector according to Claim 54.

57. (new) A pharmaceutical composition comprising a nucleic acid molecule according to Claim 50 and a pharmaceutically-acceptable carrier.

58. (new) A kit comprising in one or more containers, a pharmaceutical composition according to Claim 57.